An interesting approach has been proposed to differentiate malignant glioneuronal tumors (MGNTs) as a subclass of the WHO grade III and IV malignant gliomas. MGNT histologically resemble any WHO grade III or IV glioma but have a different biological behavior, presenting a survival twice longer as WHO glioblastomas and a lower occurrence of metastases. However, neurofilament protein immunostaini...

Introduction: An arterial input function (AIF), plasma concentration versus time curve, for an MR contrast agent (MRCA) is used to estimate the blood–brain barrier (BBB) permeability of microvessels and several other vascular related parameters. In dynamic contrast-enhanced MRI (DCE-MRI), an intravenous step-down infusion (SDI) procedure that maintains a constant gadolinium-diethylenetriaminepe...

The aim of this study was to assess the potential of dynamic contrast-enhanced (DCE) MRI to predict and evaluate functional outcomes after renal artery revascularization for renal artery stenosis (RAS). The single-kidney glomerular filtration rate (SK-GFR) was measured in 15 patients with atherosclerotic RAS with DCE-MRI and radioisotopes at baseline and 4 mo after revascularization. DCE-MRI al...

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is widely used to evaluate tumor permeability, yet measurements have not been directly validated in brain tumors. Our purpose was to compare estimates of forward leakage K(trans) derived from DCE-MRI to the estimates K obtained using [(14)C]aminoisobutyric acid quantitative autoradiography ([(14)C]AIB QAR), an established method of ...

BACKGROUND EndoTAG-1 (ET), a novel formulation of cationic liposomes carrying embedded paclitaxel (Taxol), shows antitumoral activity, targeting tumor endothelial cells in solid tumors. Patients with advanced metastatic cancer were evaluated investigating effects on pharmacokinetics and tumor vasculature using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and contrast-enhanced ...

Introduction: Increased microvessel density and increased permeability of the vascular bed are important biomarkers of malignancy and are detected in aggressive breast cancer. These parameters can be assessed by dynamic contrast-enhanced MRI (DCE-MRI) that has been used to determine the tumor grade, extent of disease, and treatment response (1, 2). In breast cancer DCE-MRI studies have reported...

Dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) represents an emerging method for the prediction of biomarker responses in cancer. However, DCE images remain difficult to analyze and interpret. Although pharmacokinetic approaches, which involve multi-step processes, can provide a general framework for the interpretation of these data, they are still too complex for robust and a...

As prostate cancer is a biologically heterogeneous disease for which a variety of treatment options are available, the major objective of prostate cancer imaging is to achieve more precise disease characterization. In clinical practice, magnetic resonance imaging (MRI) is one of the imaging tools for the evaluation of prostate cancer, the fusion of MRI or dynamic contrast-enhanced MRI (DCE-MRI)...

PURPOSE Tumor hypoxia is a major cause of radiation resistance, often present in various solid tumors. Dynamic [18 F]-fluoromisonidazole (FMISO) PET imaging is able to reliably assess tumor hypoxia. Comprehensive characterization of tumor microenvironment through FMISO-PET and dynamic contrast enhanced (DCE) MR multimodality imaging might be a valuable alternative to the dynamic FMISO-PET acqui...